Business Wire

Cellular Regenerative Therapy Greeted by French Minister of Health

Del

After European authorization was obtained this summer, the French and British regulatory agencies have authorized CellProthera to begin its first phase I/IIB clinical trial in Humans, starting January, 2016.

Recently, CellProthera presented its regenerative cardiac therapy to Marisol TOURAINE, French Minister of Social Affairs, Health and Women's Rights, before a large audience of journalists, investors, doctors and cabinet members. This initiative firmly places CellProthera among the key French startups in health services.

Upcoming launch of the 1 st clinical trial on Humans

Two cell therapy centers devoted to clinical trials - EFS ABG Nantes for France and Newcastle Cellular Therapies Facility for UK - have already been equipped with the StemXpand® automated system developed by CellProthera. Within nine days, the automated system increases by 20 times the blood stem cells selected in blood samples from patients who have suffered a severe heart attack.

As of January 2016, 9 clinical investigation centers, 6 in France and 3 in UK – Edinburgh, Leeds, Newcastle - will be operational. 44 patients who have just suffered from a severe heart attack will be selected and recruited by the study investigating cardiologists.

The CellProthera ProtheraCytes® treatment

About 220 ml of blood are withdrawn on an outpatient basis from each eligible patient and sent to one of the participating cell therapy centers. After the blood stem cells of each patient are expanded during 9 days in the StemXpand® automated system, the cell graft obtained will be re-injected directly into the patient’s cardiac lesion at the end of the 3rd week after the heart attack.

Beginning of 2016, the first graft should be performed by Pr. Jérôme RONCALLI - Principal Investigator of the study at the University Hospital of Toulouse-Rangueil Hospital.

After this phase of patients’ enrollment scheduled to be completed within 6 months, an additional 6-month period of data-monitoring and analysis will follow.

Next steps: extended clinical trial and new round of fundraising

A phase III clinical trial enrolling 150 patients will further be launched in Europe, US and Canada to which the marketing phase will follow. The Mulhouse biotechnological firm, which has at this point already raised almost 20M€, half of which is public funding, intends to conduct a new round of fundraising of about 25M€ very shortly.

www.cellprothera.com

Contact information

CellProthera
Paula LEE, +33-3-69-71-97-71
contact@cellprothera.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00Pressemelding

Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu

World Trade Center Gibraltar: £65m Annual Boost to Local Economy20.10.2017 09:48Pressemelding

A report detailing the social and economic impacts of World Trade Center (WTC) Gibraltar was presented to the World Trade Centers Association (WTCA) in New York this week. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005285/en/ Ed Allison-Wright of WTC Gibraltar, with Scott Ferguson, WTCA, New York (Photo: Business Wire) Following the official opening of World Trade Center Gibraltar by the Chief Minister and Deputy Chief Minister in February of this year, World Trade Center Gibraltar commissioned the independent international economic consultancy Nairne Limited, to study and report on the economic contributions of the World Trade Center to the Gibraltar economy. This comes in the midst of an unprecedented take up of the office accommodation within the state-of-the-art facility. An astonishing

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom